Compare Citius Pharmaceuticals Inc (CTXR) vs Illinois Tool Works Inc. (ITW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Illinois Tool Works Inc. — how do they compare? Citius Pharmaceuticals Inc trades at $0.5 (market cap $13.62M), while Illinois Tool Works Inc. trades at $264.13 (market cap $74.38B). The key difference: Illinois Tool Works Inc. is far larger — about 5461.1× Citius Pharmaceuticals Inc's market cap, and Illinois Tool Works Inc. pays a 2.63% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Citius Pharmaceuticals Inc for 17 Days and Illinois Tool Works Inc. for 67 Days on average.
| CTXR | ITW | |
|---|---|---|
Market Cap | $13.62M | $74.38B |
Volume | 132,438 | 1,125,477 |
Sector | Health | Industrials |
52-Week High | $1.82 | $299.60 |
52-Week Low | $0.48 | $241.07 |
Typical Hold Time | 17 Days | 67 Days |
Enterprise Value | $3.79M | $83.23B |
Dividend Yield | — | 2.63% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.4994, down 1.73% with a bearish technical signal despite oscillators showing oversold conditions. The company reported $7.1M revenue for the first nine months of 2026 from LYMPHIR commercial sales, but continues to post significant losses with a -651.27% net income margin. Recent news highlights strong commercial momentum for LYMPHIR with 44 institutions ordering the treatment since launch.
The stock presents a high-risk opportunity with analyst consensus strongly bullish (83% buy ratings, $5 price target) but fundamental challenges persist. Key risks include ongoing cash burn and execution of commercial strategy, while potential upside depends on successful LYMPHIR adoption and path to profitability.
ITW trades at $264.13, up 1.14% today, with a bearish technical signal but strong fundamentals including a 19.39% net income margin and three consecutive quarterly EPS beats. The stock is supported by a $1.72 quarterly dividend and a consensus price target of $276.86, though analyst ratings are mixed with 21.43% buy, 46.43% hold, and 32.14% sell. Recent news highlights its Dividend King status and institutional buying interest.
The outlook balances robust profitability and dividend reliability against technical weakness and modest revenue growth. Upside potential exists if earnings momentum continues, but risks include high valuation multiples and sector-specific headwinds. The stock presents a hold case for income-focused investors awaiting clearer technical improvement.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Illinois Tool Works Inc.
Illinois Tool Works is a diversified global manufacturer that produces specialized industrial equipment, consumables, and related services. The firm operates 87 global divisions through seven distinct operating segments: automotive OEM, construction products, food equipment, specialty products, test/measurement and electronics, polymers and fluids, and welding. About half of its revenue comes from its operations in North America, with the remainder originating from international markets. ITW takes a bottom-up and decentralized approach to portfolio management, with the exception that each segment must apply its 80/20 operating process modeled on the Pareto principle.
Read more on ITW →
